Spero Therapeutics reports Q4 2023 net income of $51.2M; SPR720 topline data expected 2H 2024

Spero Therapeutics, Inc.

Q4 2023 net income of $51.2M ($0.96 diluted EPS) vs $26.8M in Q4 2022; full-year net income of $22.8M ($0.43 diluted EPS).
Total revenue $73.5M in Q4 2023, up from $47.4M in Q4 2022, driven by $71.8M in GSK/Pfizer collaboration revenue.
Cash and cash equivalents $76.3M at Dec 31, 2023; received $23.8M first tranche of $95M GSK milestone, expects cash runway into late 2025.
SPR720 Phase 2a proof-of-concept topline data in NTM-PD expected in second half of 2024; Phase 3 PIVOT-PO trial for tebipenem HBr enrolling.
Sath Shukla transitioned to President & CEO in August 2023; Esther Rajavelu appointed CFO/CBO in November 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spero Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the ye, EPS $0.96 and $0.43.

Period: fourth quarter and full year ended December 31, 2023
Net income: Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the ye
EPS: $0.96 and $0.43
Result: reported results

Exact text from the filing

Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the year ended December 31, 2023, or a diluted net income per share of common stock of $0.96 and $0.43, respectively.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-066825

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.